

WHO guidelines for management of EPILEPSY

Nicoline Schiess Brain Health Unit WHO

2nd International workshop on Onchocerciasisassociated epilepsy 20.09.2023



Epilepsy

0



> 50 million people worldwide have epilepsy

- 7.6 people per every 1000 will have epilepsy at some point in their life
- An estimated 125 000 deaths each year are related to epilepsy


Treatment gap of >75% in most low-income countries


- 0.03 neurologists per 100 000 population in LMIC
- Access to antiseizure medicines is uneven
- About half of all people with epilepsy have comorbid conditions



- Risk of premature death is x 3 times that of the general population
- Increased risk of injury due to seizures
- Increased risk of mental health conditions
- Reduced prospects of completing schooling and being employed

Key initiatives in reducing the epilepsy burden





World Health Organization The Intersectoral global action plan on epilepsy and other neurological disorders was adopted in May 2022





75th World Health Assembly



Vision

- A world in which brain health is valued, promoted and protected across the life course;
- neurological disorders are prevented, diagnosed and treated, and premature mortality and morbidity are avoided;
- people affected by neurological disorders and their carers attain the highest possible level of health with equal rights, opportunities, respect and autonomy.

Goals

- To **reduce the stigma, impact and burden** of neurological disorders, including associated mortality, morbidity and disability, and
- to **improve the quality of life** of people with neurological disorders, their carers and families.



5 strategic objectives

Proposed

actions for:

- Member States
- WHO Secretariat
- International and National Partners

10 global targets:

Countries can set their own national targets, taking into account national circumstances and challenges



Prioritization and governance

- Advocacy
- Policy, plans and legislation
- Financing



Promotion and prevention

- Promoting healthy behaviour across life
- Infectious disease control
- Preventing head/spinal trauma
- Reducing environmental risks
- Promotion of optimal brain development in children and adolescents



Research, innovation and information

- systems
- Investment in research
- Data and information systems



World Health Organization

Diagnosis, treatment and care

- Care pathways
- Medicines, diagnostics & other health products
- Health workers' capacity, training and support
- Carer support



Public health approach to epilepsy

- Access to services for epilepsy
- Engagement and support for people with epilepsy
- Epilepsy as an entry point



Strategic objective 5

To strengthen the public health approach to epilepsy

Global targets

Global target 5.1:

By 2031, countries will have increased service coverage for epilepsy by 50% from the current coverage in 2021.

Global target 5.2:

80% of countries will have developed or updated their legislation with a view to promote and protect the human rights of people with epilepsy by 2031.

5.1 Access to services for epilepsy

- Development of models of care that promote high-quality peoplecentred primary care, including referral and specialist services, monitoring and evaluation;
- **Training** of the health and care workforce in management and prevention;
- Improving **medicine** access, availability and affordability.

5.2 Engagement and support for people with epilepsy

- Support **policies and laws** for persons living with epilepsy, improve public attitudes, reduce stigma;
- **Involve people with epilepsy,** their carers and organizations in advocacy, policy, planning, legislation, service provision, monitoring and research in epilepsy;
- Providing information that empowers people
 with epilepsy to make informed choices and
 decisions about their care.

5.3 Epilepsy as an entry point for other neurological disorders

 Expansion of epilepsy services including health workforce capacity, epilepsy diagnostics, procurement systems to other conditions



Tools to support implementation of the Intersectoral global action plan



Improving the lives of people with epilepsy: a technical brief

- Based on the guiding principles of IGAP, including gender, equity and human rights
- Uses the model of levers, or domains, from the Operational framework for primary health care by WHO and UNICEF, to list clear actions to be taken for epilepsy care
- Each lever has actions listed on the **policy level** and the **operational level**
- For each lever, there are resources, case studies, and stakeholders listed who are best positioned to take these actions
- Actions should be customized according to the local setting and needs

Improving the lives of people with epilepsy:





Levers for change


- Political commitment and leadership
- *Governance and policy frameworks*
- Funding and allocation of resources
- Engagement of community and other stakeholders
- Models of care
- Healthcare workforce
- *Medicines and other health products*
- Monitoring and evaluation
- o *Research*
- Systems for improving quality of care
- o Digital technologies for health

15 years of mhGAP: Overview of milestones


- The Mental Health Gap Action Programme (mhGAP) was launched in 2008 to support scaling up services for priority MSD conditions, including epilepsy
- The primary audience for the mhGAP guideline are non-specialized health workers at first and second-level health-care facilities.
- An algorithm-based intervention guide was launched in 2010, followed by guideline and IG updates in 2015 and 2019.
- Guideline is currently being updated with launch planned for November 2023













2019



mhGAP impact





Review > Evid Based Ment Health. 2021 Apr 26;24(3):124-130. doi: 10.1136/ebmental-2021-300254. Online ahead of print.

WHO mental health gap action programme (mhGAP) intervention guide: updated systematic review on evidence and impact

Roxanne Keynejad ¹, Jessica Spagnolo ² ³, Graham Thornicroft ⁴




mhGAP epilepsy and seizures module



Includes recommendations on assessment and treatment of acute and chronic generalized seizures in adults and children

- Recommendations for specific populations
 - women and girls of childbearing potential
 - adults and children with HIV
 - individuals with intellectual disability.



mhGAP: 2015 recommendations

Evidence-based recommendations for management of epilepsy and seizures in non-specialized health settings

- Anti-epileptic medications for management of acute convulsive seizures when no intravenous access is available
- First-line anti-epileptic medication for management of acute convulsive seizures, when intravenous access is available
- Anti-epileptic medications for management of established status epilepticus
- Antiepileptic drug treatment after first unprovoked seizure
- Standard antiepileptic drugs (phenobarbital, phenytoin, carbamazepine, valproic acid) for management of convulsive epilepsy in adults and children
- Anti-epileptic medications for adults and children with HIV
- Anti-epileptic medicines for medication resistant convulsive epilepsy
- Management of epilepsy in women of child bearing age
- Antiepileptic drug therapy in individuals with intellectual disability and epilepsy
- When to discontinue antiepileptic drug treatment in adults and children
- Pharmacologic Interventions for prophylaxis of recurrence of febrile seizures
- The role of diagnostic tests in the management of seizures and altered consciousness, particularly by non-specialists in low and middle income countries
- Diagnosis of convulsive epilepsy by non-specialist health care providers
- Role of EEG in management of convulsive epilepsy

14

- Role of neuroimaging in management of convulsive epilepsy
- Psychological interventions in adults and children with epilepsy

https://www.who.int/publications/i/item/9789241549417

mhGAP epilepsy questions in 2023 update

EPI1: In adults with established status epilepticus, i.e. seizures persisting after the first line agent (Benzodiazepine-resistant status epilepticus), which anti-seizure medications are associated with better clinical outcomes (stopping seizures and with less adverse effects)?

EPI2: In children with established status epilepticus, i.e. seizures persisting after the first line agent (Benzodiazepine-resistant status epilepticus), which anti-seizure drugs are associated with better clinical outcomes (stopping seizures and with less adverse effects)?

EPI3: For adults and children with epilepsy, which anti-seizure medications are effective and safe?

EPI4: What is the effectiveness and safety of anti-seizure medications in women of childbearing age?

EPI5: Which interventions are effective in preventing epilepsy related mortality including sudden unexpected death of someone with epilepsy (SUDEP)?



World Health Organization

Next steps: Update of mhGAP derivative products

(will all be updated following November 2023 launch of guidelines)



Key changes in 2023 update:

- 1. Inclusion of intravenous levetiracetam for established status epilepticus (now on EML) in adults and children
- 2. Revision of anti-seizure medications for adults and children to include levetiracetam (now on EML)
- 3. Strong recommendation against use of sodium valproate in women and girls of childbearing potential due to risk of teratogenic effects
- 4. New recommendation on use of nocturnal supervision for prevention of SUDEP



Improving access to medicines for neurological disorders




I - Landscape analysis -

Understand barriers, identify opportunities, and gather information on development, availability, distribution, provision, and use of medicines for neurological disorders especially in LMICs

ll – Global approach

Based on a global consultation, develop an approach to increase access to medications for neurological disorders including for epilepsy and Parkinson disease



III - Updating EMLs

The recent update of the WHO Model Essential Medicines List includes the addition of three medicines for treatment of Multiple Sclerosis and the addition of Levetiracetam for treatment of epilepsy

IV - Country projects

Demonstration projects in two proposed countries in Africa to understand barriers and identify interventions to improve access

Country work



Ghana & United Republic of Tanzania

- Two-day workshop with representation from policy makers, PLE, service providers, civil society, and other groups
- Epilepsy advocacy meeting to raise the profile of epilepsy in the country and discuss improving access to medicines for neurological disorders
- Ghana:
 - WHO is currently supporting efforts to improve awareness of neurological disorders, and consequently demand for medicines
 - update of national standard treatment guidelines and national EML

• Tanzania:

- Establishment of a National Epilepsy Committee
- Identifying challenges and actions to improving access to medicines for neurological disorders;





Thank you

CODE

14